Molecular imaging in sarcoidosis

Current Opinion in Pulmonary Medicine

Volumn 17, Issue 5, 2011, Pages 325-331

  Mañá, Juan ^a   Gámez, Cristina ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Cardiac sarcoidosis; MRI; neurosarcoidosis; PET; sarcoidosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM 67; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PENTETATE TECHNETIUM TC 99M;

ANATOMY; COMPUTED TOMOGRAPHY SCANNER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; GRANULOMA; HEART VENTRICLE FUNCTION; HUMAN; IMAGE ENHANCEMENT; INFLAMMATION; LUNG SARCOIDOSIS; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; REVIEW; SARCOIDOSIS; SYSTEMIC DISEASE;

FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80051799774     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283480d36     Document Type: Review

References (59)

1. 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography. Clin Chest Med 1997;18:799-811. (Pubitemid 27525442)
2. Basu S, Saboury B, Werner T, Alavi A. Clinical utility of FDG-PET and PET/CTin nonmalignant thoracic disorders. Mol Imaging Biol 2010 [Epub ahead of print].
3. Mañá J. Magnetic resonance imaging and nuclear imaging in sarcoidosis. Curr Opin Pulm Med 2002;8:457-463. (Pubitemid 34836953)
4. Sulavik SB, Spencer RP, Weed DA, et al. Recognition of distinctive patterns of gallium-67 distribution in sarcoidosis. J Nucl Med 1990;31:1909-1914.
5. Sulavik SB, Spencer RP, Palestro CJ, et al. Specificity and sensitivity of distinctive chest radiographic and/or 67gallium images in the noninvasive diagnosis of sarcoidosis. Chest 1993;103:403-409. (Pubitemid 23070734)
6. Costabel U, Bonella F, Ohshimo S, Guzman J. Diagnostic modalities in sarcoidosis: BAL, EBUS, and PET. Semin Respir Crit Care Med 2010;31:404-408.
7. Keijsers RG, Grutters JC, van Velzen-Blad H, et al. 18FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis. Eur J Nucl Med Mol Imaging 2010;37:1181-1188.
8. Nishiyama Y, Yamamoto Y, Fukunaga K, et al. Comparative evaluation of 18FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med 2006;47:1571-1576. (Pubitemid 47545019)
9. Keijsers RG, Grutters JC, Thomeer M, et al. Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of 67Ga imaging and 18F-FDG PET. Q J Nucl Med Mol Imaging 2010;62:1-6. This study compares the sensitivity of 18F-FDG PET and 67Ga scan in the assessment of intrathoracic and extrathoracic sarcoidosis.
10. Abehsera M, Valeyre D, Grenier P, et al. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. Am J Roentgenol 2000;174:1751-1757. (Pubitemid 30346752)
11. Braun JJ, Kessler R, Constantinesco A, Imperiale A. 18FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008;35:1537-1543.
12. Kruger S, Buck AK, Mottaghy FM, et al. Use of integrated FDG-PET/CT in sarcoidosis. Clin Imaging 2008;32:269-273. (Pubitemid 351899275)
13. Prabhakar HB, Rabinowitz CB, Gibbons FK, et al. Imaging features on MDCT, FDG PET, and PET/CT. AJR 2008;190:S1-S6. (Pubitemid 351304484)
14. Teirstein AS, Machac J, Almeida O, et al. Results of whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007;132:1949-1953.
15. Aide N, Allouache D, Ollivier Y, et al. Early 2'-Deoxy-2'-[18F]Fluoro-D- Glucose PET metabolic response after corticosteroid therapy to differentiate cancer from sarcoidosis and sarcoid-like-lesions. Mol Imaging Biol 2009;11:224-228.
16. Keijsers RGM, Verzijlbergen JF, van Diepen DM, et al. 18FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008;25:143-150.
17. Kaira K, Oriuchi N, Otani Y, et al. Diagnostic usefulness of fluorine-18-amethyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 2007;131:1019-1027. (Pubitemid 46608702)
18. Akbar JJ, Meyer CA, Shipley RT, Vagal AS. Cardiopulmonary imaging in sarcoidosis. Clin Chest Med 2008;29:429-443. (Pubitemid 351778216)
19. Sharma S. Cardiac imaging in myocardial sarcoidosis and other cardiomyopathies. Curr Opin Pulm Med 2009;15:507-512.
20. Tahara N, Tahara A, Nitta Y, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. J Am Coll Cardiol 2010;3:1219-1228.
21. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18FDG PET in identification of cardiac sarcoidosis. J Nucle Med 2004;45:1989-1998. (Pubitemid 47611626)
22. Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005;26:1538-1543. (Pubitemid 41373496)
23. Langah R, Spicer K, Gebregziabher M, Gordon L Effectiveness of prolonged fasting 18F-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009;16:801-810.
24. 18FDG PET. J Nucl Med 2003;44:1030-1036. (Pubitemid 39663376)
25. Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008;35:933-941.
26. Nunes H, Freynet O, Naggara N, et al. Cardiac sarcoidosis. Semin Respir Crit Care Med 2010;31:428-441. Updated and extensive review of the main topics of cardiac sarcoidosis: clinical expression, diagnostic tests and treatment.
27. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J 2009;157:9-21.
28. Dubey N, Miletich RS, Wasay M, et al. Role of fluorodeoxyglucose positron emission tomography in the diagnosis of neurosarcoidosis. J Neurol Sci 2002;205:77-81. (Pubitemid 36158997)
29. Aide N, Benayoum M, Kerrou K, et al. Impact of [18F]-fluorodeoxyglucose ([18F]-FDG) imaging in sarcoidosis: unsuspected neurosarcoidosis discovered by [18F]-FDG PET and early metabolic response to corticosteroid therapy. Br J Radiol 2007;80:e67-e71.
30. Nakazara A, Ikeda K, Ito Y, et al. Usefulness of dual 67Gaand 99mTc-sestamibi single-photon-emission CT scanning in the diagnosis of cardiac sarcoidosis. Chest 2004;126:1372-1376. (Pubitemid 39391275)
31. Imai E, Kaminaga T, Takada K, et al. Radioactive defect on I-123 MIBG myocardial SPECT imaging in a patient with cardiac sarcoidosis. Clin Nucl Med 2002;27:729-730. (Pubitemid 38295182)
32. Hoitsma E, Faber CG, van Kroonenburgh MJPG, et al. Cardiac sympathetic dysfunction and small fiber neuropathy: a common problem in sarcoidosis? Sarcoidosis Vasc Diffuse Lung Dis 2005;22:43-50. (Pubitemid 40444733)
33. Van Kroonenburgh M, Mostard R, Vöö S. Metaiodobenzylguanidine scintigraphy in pulmonary and cardiac disease. Curr Opin Pulm Med 2010;16:511-515.
34. Watanabe N, Tanada S, Sasaki Y. Pulmonary clearance of aerosolized 99mTc-DTPA in sarcoidosis I patients. Q J Nucl Med Mol Imag 2007;51:82-90. (Pubitemid 46824665)
35. Baughman RP, Fernandez M. Radionuclide imaging in interstitial lung disease. Curr Opin Pulm Med 1996;2:376-379. (Pubitemid 126440627)
36. Smith JK, Matheus MG, Castillo M. Imaging manifestations of neurosarcoidosis. Am J Roentgenol 2004;182:289-295. (Pubitemid 38116564)
37. Spencer TS, Campellone JV, Maldonado I, et al. Clinical and magnetic resonance imaging manifestations of neurosarcoidosis. Semin Arthritis Rheum 2004;34:649-661.
38. Terushkin V, Stern BJ, Judson MA, et al. Neurosarcoidosis. Presentations and management. Neurologist 2010;16:2-15. Extensive review of neurosarcoidosis focused on the progress during the past decade, including diagnosing imaging techniques and newer therapies with immunosuppressive and biologic agents.
39. Vinas FC, Rengachary S. Diagnosis and management of neurosarcoidosis. J Clin Neurosci 2001;8:505-513. (Pubitemid 33089498)
40. Lury KM, Smith JK, Matheus MG, et al. Neurosarcoidosis-review of imaging findings. Semin Roentgenol 2004;39:495-504.
41. Bihan H, Christozova V, Dumas JL, et al. Sarcoidosis. Clinical, hormonal, and magnetic resonance imaging (MRI) manifestations of hypothalamic-pituitary disease in 9 patients and review of the literature. Medicine 2007;86:259-268. (Pubitemid 47415004)
42. Vargas DL, Stern BJ. Neurosarcoidosis: diagnosis and management. Semin Respir Crit Care Med 2010;31:419-427.
43. Varron L, Broussolle C, Candessanche JP, et al. Spinal cord sarcoidosis: report of seven cases. Eur J Neurol 2009;16:289-296.
44. Cohen-Aubart F, Galanaud D, Grabli D, et al. Spinal cord sarcoidosis. Clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine 2010;89:133-140. Retrospective case-control study of 31 patients with spinal cord sarcoidosis compared with 30 patients with other myelopathies.
45. Shah R, Roberson GH, Cure JK. Correlation of MR imaging findings and clinical manifestations in neurosarcoidosis. Am J Neuroradiol 2009;30:953-961.
46. Santos E, Shaunak S, Renowden S, Scolding NJ. Treatment of refractory neurosarcoidosis with infliximab. J Neurol Neurosurg Psychiatry 2010;81:241-246.
47. Vignaux O. Cardiac sarcoidosis: spectrum of MRI features. AJR Am J Roentgenol 2005;184:249-254. (Pubitemid 40040938)
48. Tadamura E, Yamamura M, Kubo S, et al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. AJR 2005;185:110-115.
49. Ichinose A, Otani H, Oikawa M, et al. MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. AJR Am J Roentgenol 2008;191:862-869.
50. Cheong BYC, Muthupillai R, Nemeth M, et al. The utility of delayed-enhancement magnetic resonance imaging for identifying nonischemic myocardial fibrosis in asymptomatic patients with biopsy-proven sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2009;26:39-46.
51. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-1977.
52. Smedema JP, van Kroonenburg MPG, van Geuns RJ, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005;45:1683-1690.
53. Smedema JP, Snoep G, van Kroonenburg MPG, et al. The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest 2005;128:1629-1637. (Pubitemid 41324457)
54. Matoh F, Satoh H, Shiraki K, et al. The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. J Cardiol 2008;51:179-188. (Pubitemid 351718494)
55. Shimada T, Shimada K, Sakane T, et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 2001;110:520-527.
56. Vignaux O, Dhote R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis. A 1-year follow-up. Chest 2002;122:1895-1901. (Pubitemid 36051121)
57. Metha D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis. Diagnostic and prognostic value of outpatient testing. Chest 2008;133:1426-1435. (Pubitemid 351893001)
58. Moore SL, Teirstein A, Golimbu C. MRI of sarcoidosis patients with musculoskeletal symptoms. AJR Am J Roentgenol 2005;185:154-159.
59. Mortele KJ, Ros PR. Imaging of diffuse liver disease. Semin Liver Dis 2001;21:195-212. (Pubitemid 32552251)